• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎体征整体评估与体表面积乘积产品的初步验证。

Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis.

机构信息

Department of Dermatology, Oregon Health & Science University, Portland, Oregon.

School of Medicine, Oregon Health & Science University, Portland, Oregon.

出版信息

J Am Acad Dermatol. 2021 Feb;84(2):283-289. doi: 10.1016/j.jaad.2020.05.095. Epub 2020 May 23.

DOI:10.1016/j.jaad.2020.05.095
PMID:32454101
Abstract

BACKGROUND

Current valid instruments that measure the signs of atopic dermatitis in clinical trials may not be suitable for clinical practice because of their complexity. The product of a clinician-derived 5-point signs global assessment and body surface area (SGA × BSA) may represent a simple approach to quickly assess the severity of signs in patients with atopic dermatitis in clinical practice.

OBJECTIVES

Evaluate the basic measurement properties of the SGA × BSA.

METHODS

Retrospective chart review of patients with atopic dermatitis treated in an outpatient dermatology clinic at Oregon Health & Science University from 2015 to 2018 who had a recorded BSA and SGA.

RESULTS

We identified 138 patients completing 325 clinic visits. SGA × BSA demonstrated strong and statistically significant (P < .001) correlations with the Eczema Area and Severity Index (r = 0.91, n = 19), average daily pruritus (r = 0.71, n = 177), patient global assessment (r = 0.74, n = 170), and a derived global scale composed of the average of 4 signs rated between 0 and 3 (r = 0.77, n = 282). Acceptability, responsiveness, and floor or ceiling effects of the measure were deemed adequate. Severity banding was maximized at 1, 21, and 87 (κ = 0.4902).

LIMITATIONS

The patient cohort was gathered exclusively from a tertiary care clinic setting in the Pacific Northwest and lacked ethnic diversity.

CONCLUSIONS

The results from this study suggest that SGA × BSA is a valid and feasible instrument for atopic dermatitis signs in clinical practice.

摘要

背景

目前用于临床试验的评估特应性皮炎体征的有效工具可能因过于复杂而不适用于临床实践。基于临床医生的 5 分制体征整体评估与体表面积(SGA×BSA)的乘积可能是一种简单方法,可快速评估临床实践中特应性皮炎患者的体征严重程度。

目的

评估 SGA×BSA 的基本测量特性。

方法

对俄勒冈健康与科学大学皮肤科门诊于 2015 年至 2018 年期间就诊、有记录的体表面积和 SGA 的特应性皮炎患者进行回顾性图表审查。

结果

我们共确定了 138 例完成了 325 次就诊的患者。SGA×BSA 与湿疹面积和严重程度指数(EASI)(r=0.91,n=19)、平均每日瘙痒(r=0.71,n=177)、患者整体评估(r=0.74,n=170)和由 4 项评分在 0 到 3 之间的体征组成的平均评分衍生的整体评分(r=0.77,n=282)均具有强烈的、具有统计学意义的相关性(P<0.001)。该测量方法的可接受性、反应性和下限或上限效应被认为是充分的。严重程度分级的最佳划分是 1、21 和 87(κ=0.4902)。

局限性

该患者队列仅来自西北太平洋地区的三级护理诊所,且缺乏种族多样性。

结论

本研究结果表明,SGA×BSA 是一种在临床实践中评估特应性皮炎体征的有效且可行的工具。

相似文献

1
Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis.特应性皮炎体征整体评估与体表面积乘积产品的初步验证。
J Am Acad Dermatol. 2021 Feb;84(2):283-289. doi: 10.1016/j.jaad.2020.05.095. Epub 2020 May 23.
2
Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.特应性皮炎临床体征评估:系统评价和建议。
J Allergy Clin Immunol. 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12.
3
Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.特应性皮炎青少年和成人患者的湿疹面积和严重程度指数(EASI)、改良 EASI、特应性皮炎评分(SCORAD)、客观 SCORAD、特应性皮炎严重程度指数和体表面积严重程度分层。
Br J Dermatol. 2017 Nov;177(5):1316-1321. doi: 10.1111/bjd.15641. Epub 2017 Oct 1.
4
Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.特应性皮炎成人患者报告结局测量信息系统全球健康量表的有效性和信度。
J Am Acad Dermatol. 2021 Sep;85(3):636-644. doi: 10.1016/j.jaad.2021.01.033. Epub 2021 Jan 20.
5
Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.特应性皮炎儿童和成人中研究者整体评估与体表面积乘积的测量属性
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):180-187. doi: 10.1111/jdv.16846. Epub 2020 Sep 1.
6
Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children.研究者全球评估与体表面积乘积(IGAxBSA):一种简便实用的替代湿疹面积和严重程度指数的方法,用于评估儿童特应性皮炎的严重程度。
J Am Acad Dermatol. 2020 May;82(5):1187-1194. doi: 10.1016/j.jaad.2020.01.023. Epub 2020 Jan 21.
7
Measurement properties of the Patient-Reported Outcomes Information System (PROMIS ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.患者报告结局信息系统(PROMIS)瘙痒问卷的测量属性:成人特应性皮炎患者的瘙痒严重程度评估
Br J Dermatol. 2020 Nov;183(5):891-898. doi: 10.1111/bjd.18978. Epub 2020 May 10.
8
Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.患者导向湿疹量表与患者导向特应性皮炎评分与湿疹面积和严重程度指数及其他特应性皮炎衡量指标的比较:验证研究。
Ann Allergy Asthma Immunol. 2020 Jul;125(1):78-83. doi: 10.1016/j.anai.2020.03.006. Epub 2020 Mar 18.
9
Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement.临床实践中特应性皮炎体征的测量:HOME-CP 共识声明。
JAMA Dermatol. 2024 Aug 1;160(8):878-886. doi: 10.1001/jamadermatol.2024.1162.
10
Measuring long-term disease control in patients with atopic dermatitis: A validation study of well-controlled weeks.测量特应性皮炎患者的长期疾病控制情况:一项关于病情良好控制周数的验证研究。
J Allergy Clin Immunol. 2017 Dec;140(6):1580-1586. doi: 10.1016/j.jaci.2017.02.043. Epub 2017 Apr 26.

引用本文的文献

1
Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.按种族和肤色划分的特应性皮炎患者报告结局评估工具的心理测量学特性的差异:系统评价。
J Invest Dermatol. 2022 Feb;142(2):364-381. doi: 10.1016/j.jid.2021.06.033. Epub 2021 Aug 2.